Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1 1

Status

Recruiting 2Active not recruiting 2

Sponsor Class

OTHER 2NIH 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 95Gynecologic 32Breast 27Head & Neck 19Gastrointestinal 13Genitourinary 11Other solid neoplasm 8CNS 6Sarcoma 4Tumor-Agnostic 3Lymphoid 3Endocrine 3Dermatologic 3

Conditions

Sarcoma 2Triple Negative Breast Neoplasms 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Pathologic Complete Response 1Neoplasms 1Malignant mesenchymal tumor 1Hemangiosarcoma 1Endometrial Neoplasms 1Carcinosarcoma 1Breast Neoplasms 1

Interventions

Specimen Handling 27Magnetic Resonance Spectroscopy 23Cyclophosphamide 16Biopsy 15Doxorubicin 14pembrolizumab 12X-Rays 12Radiation 12Radiotherapy 10Temozolomide 9Phantoms, Imaging 9Vincristine 7Irinotecan 7Nivolumab 6Ifosfamide 6atezolizumab 5Gemcitabine 5palbociclib 4liposomal doxorubicin 4fludarabine 4cemiplimab 4cabozantinib 4Immunoglobulin G 4Imatinib Mesylate 4Etoposide 4Dactinomycin 4Carboplatin 4Bevacizumab 4selinexor 3olaparib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Carboplatin × Sarcoma × 30 days × Clear all
NCT00077285 2026-05-22

Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
65 enrolled
Sarcoma

Malignant mesenchymal tumor, Rhabdomyosarcoma, Sarcoma

NCT03715933 2026-05-22

Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

Inhibrx Biosciences, Inc

Phase 1 Recruiting
411 enrolled
Sarcoma

Sarcoma, Sarcoma, Ewing

NCT01042379 2026-05-06

I-SPY

QuantumLeap Healthcare Collaborative

Phase 2 Recruiting
5,000 enrolled
BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT03914612 2026-05-04

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
813 enrolled 16 charts 1 FDA
GynecologicSarcoma

Carcinosarcoma, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡